Stockscreener 앱 받기
188.93
0.27%
0.51
시간 외 거래:
188.93
전일 마감가:
$188.42
열려 있는:
$186.73
하루 거래량:
1.47M
Relative Volume:
0.31
시가총액:
$293.00B
수익:
$58.80B
순이익/손실:
$10.24B
주가수익비율:
57.62
EPS:
3.2788
순현금흐름:
$8.98B
1주 성능:
-1.85%
1개월 성능:
-9.44%
6개월 성능:
+147.68%
1년 성능:
+147.55%
1일 변동 폭
$186.33
$189.79
1주일 범위
$186.33
$193.96
52주 변동 폭
$61.24
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca Expands Real-World Push With New China Kidney Registry - TipRanks
AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook - TipRanks
AstraZeneca to boost cell therapy capabilities with new China investment - BioPharma Dive
Jacobio Pharma Poised To Turn A Profit From Precision Cancer Drugs - Benzinga
Wilmington Savings Fund Society FSB Cuts Stock Position in Astrazeneca Plc $AZN - MarketBeat
Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca to build cell therapy base, innovation centre in Shanghai - marketscreener.com
AstraZeneca Makes Soliris Available In Malaysia For Rare Disease Treatment - bernama
Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026 - Meyka
AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer - Smartkarma
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims - GuruFocus
Why AstraZeneca PLC (AZN) is one of the best immunotherapy stocks to buy according to hedge funds - MSN
Astrazeneca Plc $AZN Shares Sold by CIBC Private Wealth Group LLC - MarketBeat
AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach - TipRanks
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU - TradingView
Sentiment Recap: Why is AstraZeneca PLC Depositary Receipt stock going up2026 Market Trends & Fast Gain Swing Alerts - baoquankhu1.vn
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Rul - GuruFocus
Can AstraZeneca PLC Depositary Receipt expand into new marketsTrend Reversal & Real-Time Stock Entry Alerts - baoquankhu1.vn
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp - Insider Monkey
AstraZeneca receives EU approval for Imfinzi in early gastric cancer By Investing.com - Investing.com South Africa
AstraZeneca's Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer -- Update - marketscreener.com
EU backs AstraZeneca (NYSE: AZN) Imfinzi for early gastric and GEJ cancers - Stock Titan
AstraZeneca (AZN) Gains EU Approval for Imfinzi in Cancer Treatm - GuruFocus
AstraZeneca PLC Stock (ISIN: US6549022043) Gains Momentum on EU Imfinzi Approval for Gastric Cancer - AD HOC NEWS
EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer - marketscreener.com
Holocene Advisors LP Acquires 1,807,565 Shares of Astrazeneca Plc $AZN - MarketBeat
Fayez Sarofim & Co Has $298.78 Million Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca's Imfinzi receives EU approval - Sharecast.com
Centiva Capital LP Takes Position in Astrazeneca Plc $AZN - MarketBeat
Capitolis Liquid Global Markets LLC Purchases New Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Shares Purchased by Bamco Inc. NY - MarketBeat
Bank of America Corp DE Boosts Holdings in Astrazeneca Plc $AZN - MarketBeat
ASTRAZENECA : Berenberg keeps its Buy rating - marketscreener.com
EU Approves AstraZeneca’s Imfinzi With FLOT Chemotherapy For Early Gastric Cancer - DirectorsTalk Interviews
Ameriprise Financial Inc. Boosts Stock Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca's Imfinzi Combo Receives EU Approval for Early Gastric Cancer - marketscreener.com
Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers - AstraZeneca
AstraZeneca PLC Stock (ISIN: US6549022043) Faces Valuation Scrutiny Amid Strong Oncology Momentum - AD HOC NEWS
AstraZeneca Abivax Talks Highlight Biotech Expansion And Valuation Upside Potential - Yahoo Finance
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment - Insider Monkey
AstraZeneca PLC Stock (ISIN: US6549022043) Under Pressure as Sector Headwinds Mount - AD HOC NEWS
Astrazeneca Plc $AZN Shares Sold by Elevation Point Wealth Partners LLC - MarketBeat
Crawford Investment Counsel Inc. Buys 27,213 Shares of Astrazeneca Plc $AZN - MarketBeat
Calydon Capital Has $830,000 Stake in Astrazeneca Plc $AZN - MarketBeat
Cinctive Capital Management LP Boosts Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Shares Bought by Clark Capital Management Group Inc. - MarketBeat
AZN Stock Quote Price and Forecast - CNN
Market Outlook: Should I hold or sell AstraZeneca PLC Depositary Receipt nowQuarterly Trade Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
Towarzystwo Funduszy Inwestycyjnych PZU SA Sells 12,300 Shares of Astrazeneca Plc $AZN - MarketBeat
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
자본화:
|
볼륨(24시간):